MedTrace Logo

URINARY VEGF Levels in GBM Patients on Radiation Treatment Protocol

NCT00392548 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2006-10-26

No results posted yet for this study

Summary

Study of the urinary vascular endothelial growth factor (VEGF) levels in patients with glioblastoma, receiving standard therapy.

Hypothesis: that urinary VEGF levels can serve as a predictor of treatment response and survival.

Conditions

Sponsors & Collaborators

  • Radiation Therapy Oncology Group

    collaborator NETWORK

  • Tel-Aviv Sourasky Medical Center

    lead OTHER_GOV

Principal Investigators

  • Deborah T Blumenthal, MD · Tel-Aviv Sourasky Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Completion
2006-10-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00392548 on ClinicalTrials.gov